Literature DB >> 11788223

Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy.

Barry J Maron1, Iacopo Olivotto, Pietro Bellone, Maria Rosa Conte, Franco Cecchi, Björn P Flygenring, Susan A Casey, Thomas E Gohman, Sergio Bongioanni, Paolo Spirito.   

Abstract

OBJECTIVES: We sought to assess the occurrence and clinical significance of stroke and peripheral arterial embolizations at non-central nervous system sites in a large, community-based cohort with hypertrophic cardiomyopathy (HCM).
BACKGROUND: Such vascular events are insufficiently appreciated complications of HCM for which there is limited information on occurrence, clinical profile and determinants.
METHODS: We assessed the clinical features of patients with stroke and other peripheral vascular events in a consecutive group of patients with HCM from four regional cohorts not subject to significant tertiary referral bias.
RESULTS: Of the 900 patients, 51 (6%) patients experienced stroke or other vascular events over 7 +/- 7 years, including 44 patients with stroke; 21 (41%) of these 51 patients died or were permanently disabled. The overall incidence was 0.8%/year and 1.9% for patients >60 years old. Age at first event ranged from 29 to 86 years (mean 61 +/- 14 years). Most (n = 37; 72%) events occurred in those >50 years, although 14 (28%) younger patients (< or = 50 years) also had events. Multivariate analysis showed stroke and other peripheral vascular events to be independently associated with congestive symptoms and advanced age, as well as with atrial fibrillation (in 45 [88%] of 51 patients), at the initial evaluation. The cumulative incidence of these events among patients with atrial fibrillation was significantly higher in non-anticoagulated patients as compared with patients receiving warfarin (31% vs. 18%; p < 0.05).
CONCLUSIONS: Stroke and peripheral embolizations showed a 6% prevalence rate and an incidence of 0.8%/year in a large, unselected HCM group. These profound complications of HCM, which may lead to disability and death, were substantially more common in the elderly, occurred almost exclusively in patients with paroxysmal or chronic atrial fibrillation and appeared to be reduced in frequency by anticoagulation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11788223     DOI: 10.1016/s0735-1097(01)01727-2

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  65 in total

Review 1.  Implications of arrhythmias and prevention of sudden death in hypertrophic cardiomyopathy.

Authors:  A Selcuk Adabag; Barry J Maron
Journal:  Ann Noninvasive Electrocardiol       Date:  2007-04       Impact factor: 1.468

2.  Electrocardiographic screening for hypertrophic cardiomyopathy and long QT syndrome: the drivers of cost-effectiveness for the prevention of sudden cardiac death.

Authors:  Brett R Anderson; Sean McElligott; Daniel Polsky; Victoria L Vetter
Journal:  Pediatr Cardiol       Date:  2013-09-05       Impact factor: 1.655

3.  Left atrial wall thickness and outcomes of catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy.

Authors:  Hiroshi Hayashi; Meiso Hayashi; Yasushi Miyauchi; Kenta Takahashi; Shunsuke Uetake; Ippei Tsuboi; Kenji Yodogawa; Yu-Ki Iwasaki; Wataru Shimizu
Journal:  J Interv Card Electrophysiol       Date:  2014-04-25       Impact factor: 1.900

4.  Fabry Disease Diagnosis in a Young Stroke Patient: A Case Report.

Authors:  Aslı Aksoy Gündoğdu; Dilcan Kotan; Murat Alemdar; Zeynep Özözen Ayas
Journal:  Noro Psikiyatr Ars       Date:  2018-07-17       Impact factor: 1.339

Review 5.  The Muscle-Bound Heart.

Authors:  Marwan M Refaat; Akl C Fahed; Sylvana Hassanieh; Mostafa Hotait; Mariam Arabi; Hadi Skouri; Jonathan G Seidman; Christine E Seidman; Fadi F Bitar; Georges Nemer
Journal:  Card Electrophysiol Clin       Date:  2016-03

6.  Thrombotic events in critically ill children with myocarditis.

Authors:  Kimberly Y Lin; Basavaraj Kerur; Char M Witmer; Lauren A Beslow; Daniel J Licht; Rebecca N Ichord; Beth D Kaufman
Journal:  Cardiol Young       Date:  2013-09-09       Impact factor: 1.093

7.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  Circulation       Date:  2014-03-28       Impact factor: 29.690

Review 8.  Complementary Role of Echocardiography and Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy.

Authors:  Waseem Hindieh; Raymond Chan; Harry Rakowski
Journal:  Curr Cardiol Rep       Date:  2017-09       Impact factor: 2.931

Review 9.  Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management.

Authors:  Lohit Garg; Manasvi Gupta; Syed Rafay Ali Sabzwari; Sahil Agrawal; Manyoo Agarwal; Talha Nazir; Jeffrey Gordon; Babak Bozorgnia; Matthew W Martinez
Journal:  Heart Fail Rev       Date:  2019-03       Impact factor: 4.214

10.  Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy.

Authors:  Paola Melacini; Cristina Basso; Annalisa Angelini; Chiara Calore; Fabiana Bobbo; Barbara Tokajuk; Nicoletta Bellini; Gessica Smaniotto; Mauro Zucchetto; Sabino Iliceto; Gaetano Thiene; Barry J Maron
Journal:  Eur Heart J       Date:  2010-05-31       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.